Patent ID: 11939389
Assignee: NOVARTIS AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 62:
63. A method of treating a subject having a multiple myeloma, the method comprising administering to the subject an effective amount of autologous T cells comprising a CAR, wherein the CAR comprises an anti-BCMA binding domain, a transmembrane domain, and an intracellular signaling domain comprising a primary signaling domain and a costimulatory signaling domain, wherein:
(a) the anti-BCMA binding domain comprises a VH comprising an HC CDR1 of SEQ ID NO: 86, a HC CDR2 of SEQ ID NO: 87, and a HC CDR3 of SEQ ID NO: 88, and a VL comprising an LC CDR1 of SEQ ID NO: 95, a LC CDR2 of SEQ ID NO: 96, and an LC CDR3 of SEQ ID NO: 97;
(b) the primary signaling domain comprises a functional signaling domain of CD3 zeta; and
(c) the costimulatory signaling domain comprises a functional signaling domain of 4-1BB (CD137).